The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

Novavax (NVAX) closed the most recent trading day at $6.41, making no change from the previous trading session. This change lagged the S&P 500's 1.47% gain on the day. At the same time, the Dow added ...

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

Novavax said Monday morning that the Food and Drug Administration was asking the company to run a new trial of its Covid-19 ...

WASHINGTON — Novavax’s closely watched COVID-19 vaccine is on track for full approval after additional discussions with the ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...